99 related articles for article (PubMed ID: 7108936)
1. Increased level of the complement C3 protein in endogenous hypertriglyceridemia.
Uza G; Cristea A; Cucuianu MP
J Clin Lab Immunol; 1982 Jun; 8(2):101-5. PubMed ID: 7108936
[TBL] [Abstract][Full Text] [Related]
2. Behaviour of uricemia in hyperlipoproteinemic subjects.
Zdrenghea D; Marta D; Constantinescu M; Cucuianu M
Med Interne; 1980; 18(4):385-90. PubMed ID: 7455583
[TBL] [Abstract][Full Text] [Related]
3. Increased plasma level of clotting factors VII and X in hyperlipoproteinemia.
Cucuianu M; Popescu TA; Roman S; Bedeleanu D; Păiş R
Med Interne; 1985; 23(1):37-43. PubMed ID: 3992146
[TBL] [Abstract][Full Text] [Related]
4. Increased values of antipyrine clearance in type IV hyperlipoproteinemia.
Bedeleanu D; Trif I; Lötsch JC; Cucuianu MP
Med Interne; 1986; 24(3):183-90. PubMed ID: 3775212
[TBL] [Abstract][Full Text] [Related]
5. Increased plasma antithrombin III level in hyperlipidemic subjects.
Cucuianu MP; Cristea A; Roman S; Missits I
Clin Chim Acta; 1981 Mar; 110(2-3):147-55. PubMed ID: 7226527
[TBL] [Abstract][Full Text] [Related]
6. Lack of complement factor C3, but not factor B, increases hyperlipidemia and atherosclerosis in apolipoprotein E-/- low-density lipoprotein receptor-/- mice.
Persson L; Borén J; Robertson AK; Wallenius V; Hansson GK; Pekna M
Arterioscler Thromb Vasc Biol; 2004 Jun; 24(6):1062-7. PubMed ID: 15059809
[TBL] [Abstract][Full Text] [Related]
7. Hypercatabolism of the third component of complement in patients with primary biliary cirrhosis.
Potter BJ; Elias E; Jones EA
J Lab Clin Med; 1976 Sep; 88(3):427-39. PubMed ID: 956695
[TBL] [Abstract][Full Text] [Related]
8. The effect of aging on complement activity (CH50) and complement protein levels.
Nagaki K; Hiramatsu S; Inai S; Sasaki A
J Clin Lab Immunol; 1980 Jan; 3(1):45-50. PubMed ID: 7381926
[TBL] [Abstract][Full Text] [Related]
9. [The therapeutic efficacy of bezafibrate in hyperlipoproteinemias of various types].
Noseda G; Fragiacomo C; Weidmann P; Bachmann C
Schweiz Med Wochenschr; 1980 Dec; 110(49):1875-7. PubMed ID: 7455660
[TBL] [Abstract][Full Text] [Related]
10. Pirifibrate in the treatment of hyperlipoproteinemia: types IIa, IIb, and IV.
Lopez Rodriguez J; Martorell J
Clin Ther; 1980; 3(4):234-41. PubMed ID: 7273061
[TBL] [Abstract][Full Text] [Related]
11. Clinical studies on plasma protein C. Correlation with serum cholinesterase.
Cucuianu M; Brudasca I; Trif I; Stancu A
Nouv Rev Fr Hematol (1978); 1993; 35(5):481-6. PubMed ID: 8295822
[TBL] [Abstract][Full Text] [Related]
12. [Alcohol-induced hyperlipoproteinemia].
Baumgartner HP; Filippini L
Schweiz Med Wochenschr; 1977 Oct; 107(40):1406-11. PubMed ID: 918592
[TBL] [Abstract][Full Text] [Related]
13. Variable effects of soy protein on plasma lipids in hyperlipidemic and normolipidemic hemodialysis patients.
Chen ST; Ferng SH; Yang CS; Peng SJ; Lee HR; Chen JR
Am J Kidney Dis; 2005 Dec; 46(6):1099-106. PubMed ID: 16310576
[TBL] [Abstract][Full Text] [Related]
14. [Apolipoprotein E and activity of cholesterol esters transport in type IIA and IIB hyperlipoproteinemia].
Tvorogova MG; Rozhkova TA; Semenova OA; Lupanov VP; Nuraliev EIu ; Kukharchuk VV; Titov VN
Ter Arkh; 1997; 69(12):30-3. PubMed ID: 9503530
[TBL] [Abstract][Full Text] [Related]
15. Clinical experience with bezafibrate.
Schubotz R; Schneider J; Hausmann L; Mühlfellner G; Mühlfellner O; Kaffarnik H
Artery; 1980; 8(6):553-9. PubMed ID: 7259534
[TBL] [Abstract][Full Text] [Related]
16. Pirifibrate in the treatment of hyperlipoproteinemias: a multicenter study.
Domingo AJ; Gutiérrez JA; Menéndez JA; Micó L; Muñoz M; de Oya M
Clin Ther; 1980; 3(3):219-26. PubMed ID: 7459931
[TBL] [Abstract][Full Text] [Related]
17. Hemorrheologic abnormalities in defined primary dyslipoproteinemias with both high and low atherosclerotic risks.
Otto C; Ritter MM; Richter WO; Minkenberg R; Schwandt P
Metabolism; 2001 Feb; 50(2):166-70. PubMed ID: 11229424
[TBL] [Abstract][Full Text] [Related]
18. [The effects of a short-lasting hyperthermia on the levels of complement and lysosomal enzymes in the serum of healthy and IHD-sick subjects].
Ferenciková J; Kolesár J
Allerg Immunol (Leipz); 1982; 28(2):122-8. PubMed ID: 6215845
[TBL] [Abstract][Full Text] [Related]
19. [Components of complement in patients with immediate hypersensitivity].
Anania A; Massobrio AM; Cascio B; Bosso E; Cascio G
Minerva Med; 1998 Mar; 89(3):77-81. PubMed ID: 9575333
[TBL] [Abstract][Full Text] [Related]
20. Clinical study on the effect of simvastatin on butyrylcholinesterase activity.
Muacević-Kataneca D; Bradamante V; Reinec Z; Sucić M; Poljicanin T; Busljeta I; Metelko Z
Arzneimittelforschung; 2005; 55(5):271-5. PubMed ID: 15960426
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
